ARTICLE | Data Byte
New AMD data showcase the promise and high bar for vectorized biologics
Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling
July 18, 2024 1:39 AM UTC
Interim results from Phase II trials of two wet AMD gene therapies encoding versions of aflibercept further build the case for a future in which one-time treatments with vectorized biologics supplant chronic injections of established products. Investor reaction, however, showed getting from here to there may be challenging, as even a hint of a safety issue can sink shares.
On Wednesday, 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) each presented Phase II data at the American Society of Retina Specialists Annual Scientific Meeting...